Gimeno, Juan R.Olivotto, IacopoIsabel Rodriguez, AnaHo, Carolyn Y.Fernandez, AdrianQuiroga, AlejandroAngeles Espinosa, MariGomez-Gonzalez, CristinaRobledo, MariaTojal-Sierra, LucasDay, Sharlene M.Owens, AnjaliBarriales-Villa, RobertoMaria Larranaga, JoseRodriguez-Palomares, JoseGonzalez-del-Hoyo, MaribelPiqueras-Flores, JesusReza, NosheenChumakova, OlgaAshley, Euan A.Parikh, VictoriaWheeler, MatthewJacoby, DanielPereira, Alexandre C.Saberi, SaraHelms, Adam S.Villacorta, EduardoGallego-Delgado, MariaCastro, DanielDominguez, FernandoRipoll-Vera, TomasZorio-Grima, EstherCarlos Sanchez-Martinez, JoseGarcia-Alvarez, AnaArbelo, ElenaVictoria Mogollon, MariaEugenia Fuentes-Canamero, MariaGrande, EliasPena, CarlosMonserrat, LorenzoLakdawala, Neal K.Dilema Int Cardiomyopathy Heart Fa2023-05-032023-05-032022-06-032055-5822http://hdl.handle.net/10668/21906Aims To describe the natural history of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events.Methods and results Three hundred and five patients [age 56.6 +/- 16.9 years old, 191 (62.6%) male patients] with HCM and SARS-Cov-2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS-CoV-2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty-nine (22.9%) HCM patients were hospitalized for non-ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS-CoV-2-related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12-4.51], P = 0.02291, baseline New York Heart Association class [OR per one-unit increase 4.01 (95%CI: 1.75-9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16-26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20-49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community-based SARS-CoV-2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98-2.91, P = 0.0600).Conclusions Over one-fourth of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality.enAttribution-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nd/4.0/Hypertrophic cardiomyopathyCOVID-19SARS-CoV-2 infectionHeart failureRegistryPrognosisClassificationCardiologyStatementCovid-19Diseaseresearch articleopen access10.1002/ehf2.13964https://docusalut.com/bitstream/20.500.13003/18085/1/ESC_Hear_Fail-2022-06-3.pdf805160500001